Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.

ABSTRACT:

Introduction

To evaluate the cost-effectiveness of evolocumab when added to standard of care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease (ASCVD) who cannot adequately control their low-density lipoprotein cholesterol (LDL-C) despite optimized LLT in Canada.

Methods

An incremental cost-utility analysis was conducted using a Markov cohort state transition model adapted to the Canadian setting. Analyses were conducted from a public health and societal perspective using a lifetime time horizon for Canada. Scenario analyses were conducted on the basis of recommendations from the 2021 Canadian Cardiovascular Society (CCS) dyslipidemia guidelines.

Results

In ASCVD patients with prior myocardial infarction (MI) and baseline LDL-C ≥ 

SUBMITTER: Gregoire J 

PROVIDER: S-EPMC9239938 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature